Eli Lilly and Company’s board of directors has approved a first-quarter 2026 dividend of 1.73 dollars per share on the company’s outstanding common stock. The dividend is scheduled to be paid on March 10, 2026, to shareholders of record as of the close of business on February 13, 2026.
The payout reflects a double-digit year-over-year increase in Lilly’s quarterly dividend and continues a multiyear pattern of dividend growth supported by strong commercial performance in key therapeutic areas. Lilly has reported robust revenue expansion from its diabetes and obesity franchises, as well as newer launches in neuroscience, immunology, and oncology, helping underpin its capital allocation strategy.
For industry and financial stakeholders, the move signals sustained confidence from Lilly’s board in the company’s cash generation, even as it continues to invest heavily in late-stage R&D and global manufacturing capacity. The dividend declaration also maintains Lilly’s positioning as a large-cap innovator balancing shareholder returns with pipeline and infrastructure spending, a trend closely watched across the pharmaceutical sector.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!